NKTR
What a difference a week makes for biotech stocks
Last week the biotech sector seemed in freewill. Bristol Myers Squibb (BMY) had made a deal to buy Celgene (CELG) at a whopping 54% premium to Wednesday's close and the sector dropped on the news. The prevailing theory was that the deal removed one hungry big drug...
Selling AAPL, FCX, NKTR, PXD, VIX options out of Volatility Portfolio on likelihood of continued downward trend in the market and looming expirations
In November and December I selectively added risk to my Volatility Portfolio in the expectation of a strong seasonal January Effect Rally and the odds of an end of the year bounce that would, temporarily, disrupt the developing bear market. I thought that was a...
Why Nektar is extremely oversold right now
The longs and the shorts continue to battle over Nektar Therapeutics (NKTR.) Right now the shorts have the best of that fight. No contest. The shares of this biotech fell another 1.24% today to close at $51.71. A little more than a month ago they were at $68.49. But I...
Nektar beats on earnings–more importantly FDA accepts company’s new opioid for review
I'm on vacation through August 26. I'm trying to use this down time to catch up on earnings results that I missed during the very busy second quarter earning season. After the market close on Wednesday, August 8, Nectar Therapeutics (NKTR) reported earnings of $5.33 a...
Nektar up 6.32% today on opioid data presentation
Frankly, my holdings of shares and options on Nektar Therapeutics (NKTR) are driving me nuts. The stock is just so volatile that I can barely stand it even though I'm comfortable with the long-term trajectory of the company's new non-addictive opioid and its leading...
Nektar’s 40% drop yesterday was an extreme over-reaction: What I’m doing now
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the...
Stock or options, Nektar needs some understanding and patience now
It hasn't exactly been a stellar couple of months for shares and options on Nektar Therapeutics (NKTR). The stock is down 23.1% since it hit a high of $108.44 on March 8. The August 17, 2018 call options with a strike of $90 I bought on February 25, 2018 are now down...
Positive catalysts are intact for Nektar Therapeutics
Shares of biotech rocket Nektar Therapeutics (NKTR) are down 23.25% since they traded at $106.91 on March 21, 2018. I can't find evidence that the positive catalysts that led me to recommend the stock for my Jubak Picks portfolio and the options for my Volatility...
Nektar blows away revenue projections, gives very positive guidance on drug pipeline
Shares of Nektar Therapeutics (NKTR) finished up 21.67% today to $102.87 after the biotech company announced after the close yesterday a smaller than expected fourth quarter 2017 loss of 21 cents a share (versus the Wall Street consensus projection of a 36 cents a...
Bristol-Myers puts up potential $3.6 billion in deal for 35% of a Nektar cancer drug
In the deal announced today Bristol-Myers Squibb (BMY) pays Nektar Therapeutics $1 billion upfront, $850 million for stock valued at a price of $102 a share, and a potential $1.78 billlion in milestone payments in exchange for access to NKTR 214, a drug candidate still in trials and that has shown the ability to extend the range of Bristol-Myers Opdivo
Nektar soars today on J.P. Morgan healthcare conference
Anybody still think that conferences, especially biotech conferences, don’t move stock prices? Shares of Nektar Therapeutics (NKTR) are up 7.65% today to $61.79 as of noon New York time on the company’s appearance at this week’s J.P. Morgan biotech conference. The slides from the company’s presentation today are in circulation but CEO Howard Robin doesn’t actually present until 2 p.m. New York time today.
Jim’s Stock Alerts
Download Jim’s eBook for Free
